Rein Therapeutics (RNTX)
NASDAQ:RNTX
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$1.02 - $2.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$36.45M
Enterprise Value$30.71M
Total Cash (Recent Filing)$3.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,039,032
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$10.00Price Target Upside693.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces fixed financial obligations and lowers default risk, which is important for a clinical-stage biopharma without product revenue. This structural conservatism preserves optionality, making it easier to allocate scarce cash to R&D and to negotiate future financings without heavy interest expense.
Private Note Placement Provides Near-Term LiquidityAccessing private capital via note placements under Reg D supplies non-dilutive or bridge funding and can extend runway for clinical programs. Structurally, this financing route offers speed and investor flexibility versus public offerings, reducing the immediate financing cliff risk and supporting ongoing trial execution.
Focused Clinical-Stage Pipeline In Fibrotic DiseasesA narrow, disease-focused R&D strategy concentrates expertise and resources on high unmet-need indications with significant barriers to entry. Over a multi-month horizon, this specialization can improve trial design efficiency, partnership appeal, and eventual commercialization clarity if clinical milestones are met.
Bears Say
Pre-revenue ProfileWith zero reported revenue, the company lacks operational validation and cannot self-fund development from product sales. This structural absence of commercial cash flows prolongs dependence on capital markets, increases dilution risk for shareholders, and leaves the firm vulnerable if fundraising conditions tighten.
Consistent Negative Cash GenerationSustained negative operating and free cash flow means the company must repeatedly access external financing to continue operations. Over months, this creates execution risk: constrained cash can delay trials, limit recruitment, and force unfavorable financing terms, eroding value even if scientific progress continues.
Shrinking Equity Cushion Increases Financing RiskA rapidly contracting equity base reduces the company’s loss-absorption capacity and bargaining power with investors. Structurally, that amplifies the likelihood of dilutive raises or expensive financing and constrains strategic flexibility, particularly if clinical setbacks occur or additional capital is needed quickly.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.02 and its highest was $2.40 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $36.45M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 28,039,032 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (693.65% Upside)
$10.00 (693.65% Upside)
Insider Transactions
Bought Shares
Worth $550.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-217.16%
Trailing 12-Months
Asset Growth
-48.47%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(693.65% Upside)
Technical Analysis
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
7.15% Insiders
4.47% Mutual Funds
31.09% Other Institutional Investors
52.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---